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S278 Poster Session IIinfection whit gB1+gB3 and gB2 + gB3. HCMV disease devel-
oped in 2 patients, characterized for gastrointestinal disease and
these two patients had infection with a mixture of HCMV gB
genotypes.
Conclusions: in this study the most prevalent genotype in patients
with HCMV active infection was gB genotype 1 and moreover, the
mixture of HCMV gB genotypes was associate with gastrointestinal
disease. However, this study is limited due to the small number of
patients, thus making it difficult to draw a firm conclusion regard-
ing the distribution of HCMV genotypes and their possible associ-
ation with outcome. Nevertheless, these results may be taken as
a preliminary report on the prevalence of different HCMV gB ge-
notypes in a Brazilian allogeneic HSCT population with active
HCMV infection.323
A PHASE I STUDY OF CLOFARABINE PLUS HIGH DOSE MELPHALAN AS A
CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION
Kirschbaum, M.H., Stein, A.S., Nakamura, R., Auayporn, N.,
Popplewell, L., Delioukina, M., Chen, R., Snyder, D., Conrad, J.,
Frankel, P., Forman, S.J. City of Hope National Cancer Center, Duarte,
CA
Background:Reduced intensity regimens for allo transplant suc-
cessfully replaced the alkylating agent cyclophosphamide with
the purine nucleoside antimetabolite, fludarabine, an immuno-
suppressive with a milder toxicity profile. Clofarabine is a purine
nucleoside analogue designed to exploit a double halogen strat-
egy which confers resistance to adenosine deaminase and makes
the drug more efficient than fludarabine at inhibiting ribonucle-
otide reductase and disrupting mitochondrial function, leading
to apoptosis.
Aims:To evaluate a clofarabine containing regimen as conditioning
for allogeneic stem cell transplant.
Methods: phase I dose escalation: clofarabine (dose level
one5 30 mg/m2, dose level two and three5 40 mg/m2) IV daily
days –7 to day –3 infused over 30 minutes IV, plus Melphalan
(dose level one and two, 100 mg/m2, dose level three, 140 mg/
m2) administered over 30 minutes IV on day –2. Related or un-
related allogeneic stem cells were infused on day 0. GVHD
prophylaxis: initially CSP plus mycophenelate, then tacrolimus
plus sirolimus was adopted as per COH standard of care. Pa-
tients age$ 18 years with AML, ALL, MDS in CR1, CR2 or
in relapse (up to 50% marrow blasts), not deemed eligible for
standard transplant regimens, or at high risk for relapse, are
eligible.
Results: We report on the first 2 dose levels. 10 eligible pa-
tients, all with AML, have been treated thus far, 4 Males, 6 Fe-
males, with a median age of 62 years (39 – 65). 5 patients were
in CR1, 2 patients were in CR2, and 3 patients were trans-
planted in relapse. Grade 3 non-hematologic toxicities included
fatigue, elevation of AST and LFT, diarrhea, and hyponatremia
and mucositis (in one patient). No dose limiting toxicities
(DLT) were seen in level one. One patient in dose level 2
died prior to engraftment due to hepatic, renal, and infectious
toxicities; that dose level has been expanded thus far to seven
patients and no further DLT have been seen (one accrued pa-
tient was ineligible due to mismatch). Three patients in relapse
received an unrelated donor graft, had complete engraftment
and achieved remission. Engraftment data is presented in the
table below. Mild acute skin graft versus host disease (GvHD)
was seen in two patients, with mild gut GvHD responsive to
steroids seen in one patient, and mild chronic GvHD in one
patient.
Conclusion: The combination of clofarabine and melphalan is an
adequate conditioning regimen leading to complete engraftment of
allogeneic stem cells.Dose Days* to Days* to Months
Level Patient ANC$ 0.5x109/L PLT$ 100 Follow-up** Status1 1 14 15 20 Remission
1 2 14 13 20 Remission
1 3 24 23 18 Remission
2 4*** 1 Expired
2 5 13 13 16 Remission
2 6 17 13 10 Remission
2 7 12 14 8 Remission
2 8 16 14 6 Remission
2 10 12 13 1 Remission
2 11 16 15 1 Remissionmedian 14 14 9* - From Transplant ** - Days from transplant to relapse/death or last
contact *** - Patient expired prior to engraftment.324
DYSGLYCEMIA FOLLOWING GLUCOCORTICOID THERAPY FOR ACUTE
GRAFT VS. HOST DISEASE ADVERSELY AFFECTS TRANSPLANTATION
OUTCOMES
Pidala, J.1, Kim, J.2, Alsina, M.1, Ayala, E.1, Field, T.1, Fernandez, H.1,
Kharfan-Dabaja,M.1, Ochoa, L.1, Perez, L.1, Perkins, J.1, Tomblyn,M.1,
Anasetti, C.1 1Moffitt Cancer Center, Tampa, FL; 2Moffitt Cancer Cen-
ter, Tampa, FL
Disordered glucose metabolism is a common complication of glu-
cocorticoid therapy for acute graft vs. host disease (aGVHD) after al-
logeneic hematopoietic cell transplantation (HCT). We aimed to
examine the independent impact of serum glucose parameters (max-
imum,minimum,mean, and standard deviation) on outcomes in a se-
ries of 173 recipients of HCTwho were treated with glucocorticoids
for aGVHD.Median onset of aGVHDwas 23 days (range 5 – 1112).
Patients were treated with primarily 1 mg/kg of glucocorticoids for
biopsy-confirmed aGVHD. The median duration of glucocorticoid
therapywas 271 days (range 15 – 1632).Glucose valueswere obtained
from glucocorticoid initiation date to death or last follow up, result-
ing in a total of 13,170 values. Themedian (range) values for each pa-
rameter were: maximum 292 mg/dL (128 – 694), minimum 75 mg/
dL (34 – 142), mean 146 mg/dL (86 – 327), and standard deviation
47 mg/dL (12 – 108). Baseline diabetes mellitus predicted signifi-
cantly greater maximum, mean, and standard deviation. With a me-
dian follow up of 18 months, median overall survival (OS) was 16
months (95% CI 11 – 34). On multivariable analysis, maximum glu-
cose significantly predicted OS and non-relapse mortality (NRM).
Increased variability also predicted OS and NRM. Those with mini-
mum glucose values of (0 – 60 mg/dL) had increased NRM. Values
for minimum glucose demonstrated a non-linear relationship with
OS: those with minimum glucose of (0 – 60 mg/dL) as well as those
(81 – 150 mg/dL) had significantly worsened OS compared to (61 –
80 mg/dL). Minimum glucose of (81 – 150 mg/dL) was associated
with significantly increased risk for relapse. These data demonstrate
the adverse effect of dysglycemia in patients treated with glucocorti-
coids for aGVHD, and argue for stringent glycemic control in this
setting. Further efforts to reduce the burden of aGVHD, and its as-
sociated treatment with glucocorticoids are paramount.325
ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION DOES NOT
ERASE THE IMPACT OF THE NEW PROGNOSIS CLASSIFICATION IN AML
AND THE NEGATIVE INFLUENCE OF EVI1 AND FLT3 ITD MUTATIONS
Michallet, M., Sobh, M., Hayette, S., Charlot, C., El Hamri, M.,
Tedone, N., Nicolini, F.E., Ducastelle, S., Baracco, F., Tigaud, I.,
Thomas, X. Edouard Herriot Hospital, Lyon, France
We studied 78 patients who underwent an allogeneic HSCT for
AML and for whom we had cytogenetics and molecular markers.
Poster Session II S279There were 73 de novo and 5 secondary AML. Regarding cytogenet-
ics and molecular markers: 6 were in favourable, 29 in intermediate
and 38 in unfavourable group and we found 5 Flt3 mutated, 22 Flt3
ITD+, 4 MLL mutated, 13 Hoxa9 mutated, 10 Evi1 mutated, 34
Wt1 mutated and 17 NMP mutated, 11 patients were in the good
prognosis group and 61 in the poor prognosis group. At transplant,
42 patients were in CR1, 22 in.CR1 and 14 in progressive disease,
49 received a myelo-ablative and 29 a non myelo-ablative condition-
ing. As HSC source, 27 received PBSC, 46 bone marrow and 5 cord
blood cells.With amedian follow-up of 32months, the 3-years over-
all survival was 45%612 with no significant impact of age, FAB clas-
sification, kind of AML (de novo vs secondary), HSC source (PBSC
vs BM), Flt3, MLL, HoxA9, NMP and WT1 mutations. We found
a difference of survival but not reaching the significance for Flt3 ITD
[27.5% 620 (mutated)vs 52% 612 (non mutated), p5 0.09] and
a significant difference of survival for Evi1 [48.5%614 (non mu-
tated) vs 22.5% 626 (mutated), p5 0.04]. We also showed a differ-
ence of survival not reaching the significance according to
cytogenetics with 83%630 for favourable, 53%620 for intermesiate
and 28%616 for unfavourable although we observed a very signifi-
cant difference of OS according to the new prognosis classification
between the good prognosis group with 81%624 and the poor prog-
nosis group with 38%614 (p5 0.04). In addition, we found a signif-
icant better survival for patients in 1st CR (60%616) vs.CR1
(31%622) or in progressive disease (24%622)(p5 0.009) and a sig-
nificant difference of survival according to conditioning with
54%616 for myelo-abative vs 11%618 for RIC (p\0.0001).The
multivariate analysis showed a significant impact on OS of the new
prognosis classification [HR5 3.62 [95%CI 2.89-4.35] (p5 0.03)],
disease status at transplant [HR5 151 [95%CI 1.28-1.74]
(p5 0.07)], kind of conditioning [HR5 0.32 [95%CI 0-0.7]
(p5 0.003)], Evi1 [HR5 0.33[95%CI 0-0.8] (p5 0.02)] and Flt3
ITD [HR5 0.43 [95%CI 0.07-0.78] (p5 0.02)].
The OS after allogeneic HSCT remains very poor for patients
having Evi1 mutation and Flt3ITD for whom it is fundamental to
propose new strategy of allogeneic HSCT in 1st CR as for example
allotransplant after FLAMSA regimen or haplo-identical allogeneic
HSCT.326
CD3 CELL DOSE AND OUTCOME AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Farhan, S., Mckinnon, R., Fortney, C., Divine, G., Janakiraman, N.
Henry Ford Health System, Detroit, MI
Background: Stem cell dose for transplant is determined by CD34
althoughT cells are co-infused. A clear association of CD3with clin-
ical outcome is not established. The dose of CD3 is usually not taken
into consideration except in T cell depleted transplantation. We did
a retrospective analysis to study the effect of CD3cell infused on
mortality, relapse, graft versus host disease (GVHD) and engraft-
ment.
Methods: 161 patients with allogeneic stem cell transplantation, pe-
ripheral (PSCT) and marrow, were identified from the BMT Regis-
try at Henry Ford Health System between 1999 and 2009. We
classified disease risk into 2 categories; Low risk which includes acute
leukemia and lymphoma in first complete remission or chronic my-
eloid leukemia in chronic phase. All others were considered as high
risk disease. Engraftment is defined as absolute Neutrophil count
(ANC) of 500/mm3and platelets as 20,000/mm3 per CIBMTR cri-
teria. Acute GVHD was graded according to Glucksberg system.
Results: Among 161 patients, 137 patients (85%) had PSCT and 24
(15%) had marrow transplant. Mean age was 47.72 (19-71). Patients
with high risk diseasewere 137 (85%), low risk diseasewere 24 (15%).
147 (91%) received myeloablative regimens while 14 (9%) received
a non-myeloablative one. Source of transplant was related in 117 pa-
tients (73%), unrelated in 44 (27%). 120 patients (75%) had a good
match. Mean dose of CD34 infused was 5.75106/kg (1-22.3) while
mean for CD3 infused was 1.23108/kg (0-13.4). There was a statis-
tically significant adverse correlation betweenCD3 infused and over-
all survival (p5 0.013). This was true even when adjusted for age,
match status and disease risk (HR5 1.167,p5 0.010). We did not
find association between CD3 infused and grade II-IV GVHD orrelapse. There was very small negative correlation between CD3 in-
fused and days to ANC 500 (r5 -0.14, p5 0.089). After adjustment
for the few outliers, the partial correlation was -0.15, p5 0.086.
There was also a modest positive correlation with Platelet 20000,
r5 0.36, p\0.001. After adjustment, the correlation was 0.37,
p\0.001.
Conclusion: In this small group of 161 allo-stem cell transplant, we
found that the dose of CD3 infused significantly affected the out-
come by decreasing survival and modestly affecting days to engraft-
ment. This supports the need to monitor CD3 and to be aware of it
when deciding CD34 dose to be infused. Since this is a small group,
further studies involving larger cohort of patients are needed.327
APHERESIS AND TRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS
(HPC) FROM ALLOGENEIC DONORS $60 YEARS OF AGE
Janssen, W.E., Ayala, E., Field, T., Kharfan-Dabaja, M., Ochoa, L.,
Rahn, D., Hackett, M., Coyle, D., Anasetti, C., Fernandez, H.F. Moffitt
Cancer Center, Tampa, FL
There has been reluctance to collect apheresis HPC allografts
from donors of age 60 or greater. This is predicated on concern
over relative frailty, poor venous access, reduced potential for
HPC mobilization, and reduced potential for stable engraftment of
HPC transplant. We have expanded our transplant eligibility into
patients beyond the age of 60, with the concomitant acceptance of
sibling donors of similar age. Herein we review 104 consecutive sib-
ling donors, 20 of whom were of age$60 years at the time of collec-
tion. All donors were collected beginning on day 5 of 10mcg/Kg/day
of G-CSF mobilization. Apheresis was performed using Caridian
Spectra instruments, and the volume of blood processedwas adjusted
to target a CD34 dose of 5-10million per Kg of recipient weight.We
have compared these two groups of donors for total blood volumes
(TBV) processed, CD34 cells recovered per Kg of recipient weight,
and CD34 cells recovered per TBV apheresed, using Student’s T-
test. Comparison of rates of failure to recover 5 million CD34/Kg-
recipient, requiring greater than one collection, requiring a catheter,
and of having a grade 3 or 4 reaction to apheresis were performed us-
ing Fisher’s exact test, and comparison of engraftment rates was per-
formed using the log-rank statistic. Our findings are presented in the
table. These results demonstrate that donors of age $60 years may
be successfully collected by apheresis following G-CSF mobiliza-
tion, and that the resultant grafts can be expected to produce success-
ful transplants. There no greater rate of toxicity or need for catheter
insertion associated with the collections in the older age group.
There was, however, a clear trend to reduced mobilization of
CD34+ cells, as reflected in an apparent need for more collections,
and statistically fewer CD34+ cells per blood volume leukopheresed.
In spite of this, sufficient cells to produce functional grafts were col-
lected from all donors, although a limited number of donors in both
age categories failed to collect a full 5e + 6 CD34/Kg. We conclude
that in the context of an aging demographic, allograft donors of age
$60 may be successfully employed for HPC collection. Further, we
propose that the application of plerixafor in $60 year old donors
should be investigated in the context of a growing need to collect al-
lografts from donors in this age group.Age\60 Age. 60
(n5 86) (n5 20) pBlood volumes (Mean6 Std) 5.06 3.3 6.16 3.1 0.17
CD34/RecipKg E6 (Mean6 Std) 8.36 3.1 5.86 1.7 0.001
CD34/Blood vol E7. (Mean6 Std) 18.76 11.8 11.06 7.6 0.006
\ 5E6 CD34/Kg Collected (n) 6 3 0.25
. 1 collection (n) 15 7 0.087
Catheter required (n) 25 6 0.59
Grade 31 pheresis complications 2 3 0.047
ANC500 Median days (Min-Max) 16 (10-28) 16 (13-75) 0.14
Plt20 K Median days (Min-Max) 16 (8-77) 16 (13-89) 0.30
